

Cologuard® Executing Against Our Mission


Maneesh Arora
Chief Operating Officer



Colorectal cancer: Second most lethal cancer in US

132,700 new diagnoses in 2015

49,700
Deaths in 2015





Many Americans aren't getting screened for colon cancer

42%

of Americans not current on colon cancer screening






Source: CDC MMWR 2013; 64(17);464-468 (Sabatino)

Cologuard®: At-home screening for 80M Americans





Cologuard® proven in unprecedented study



DeeP-C results

92% cancer sensitivity 69% high grade dysplasia sensitivity 87% specificity 94% sensitivity for Stages I and II cancer

serrated poly had advanged could be

Pic New York (S.H.I.) Medicine at Mounts

sensit Source: N Engl I Me

Source: N Engl J Med 2014;370:1287-97. DOI 10.1056/NEJMoa1311194 (Imperiale)

with F

42.4% with DNA testing and 20.

Steatest dimension) on colonosco

With DNA testing and 20.

Steatest dimension) on colonosco

With DNA testing and 20.

Steatest dimension) on colonosco

Hepatology, Man G.P.L. B.M.B.): an



Cologuard®: Detecting cancer when most treatable


1,000

6 people with cancer

50 people with pre-cancers, all removable



5 with early stage disease





Pathways to mobilizing Cologuard® adoption Securing Influencing Activating Physicians People Coverage exact sciences

Pathways to mobilizing Cologuard® adoption Influencing Activating Securing Physicians People Coverage exact sciences

High quality sales force generating results




Creating a results-driven field force

- Average 10 years sales experience
- Focused on high-value physicians
- Real-time data guides strategy
- Strategically aligned co-promote partner

Sales Reps on June 1



Number of physicians ordering Cologuard® rapidly expanding





The illustration includes data as of June 19th and the month of June is extrapolated through June 30th



Marketing driving awareness; sales driving volume

First-time ordering physicians






The illustration is launch to date as of June 12th











Factors that shape Cologuard® ordering



- Physicians need
 - Awareness
 - Coverage
 - Quality metrics inclusion
 - Easy to order and get results (EMR linkage)



Substantial underlying demand supports growth

~80,000
orders
through Q2

- Converting orders into completed tests need
 - Time to perform test (~30 days)
 - Complete information on order
 - Insurance coverage
 - 73% compliance rate



Most physicians order Cologuard® more than once


63%

of ordering physicians order Cologuard® more than once

Includes providers whose first order was on or before May 5th, 2015



Number of new-ordering and repeat-ordering physicians growing consistently




The illustration is launch to date as of June 19th



Investment in proprietary systems driving **business strategy** Lab Information System **Electronic** Data Call Warehouse Center Sales -CRM exact sciences

Real-time visibility drives Cologuard® sales



Propriety software enables

- Monitoring orders and results in real-time
- Engaging targeted physicians to maximize ordering
- Ensuring timely follow-up to new, 'untouched' prescribers
- Tracking Cologuard® progress from prescription to result



Cologuard® launch early takeaways

- Targeting
 - Targets are just as likely to order as non-targets
 - Targets order 17% more than non-targets
 - Real-time data driving targeting



Cologuard® launch early takeaways

- Sales frequency drives ordering
 - 3.6 calls on average before a physician orders Cologuard[®]



Frequency of sales activity after provider's first order






Investment in health systems

- 30 health systems have adopted the use of Cologuard® in their colon cancer screening programs
- 11 additional health systems are currently active in the implementation process
- ~5,000 PCPs have management support and the ability to order Cologuard® through their electronic medical record system



Significant opportunity ahead for Cologuard®



"When my rep told me about the noninvasive test with no prep, the high sensitivity, the 10,000 person study to back that up, I was sold. He also helped get me registered and set up in the system so I was ready to go."

Prescribing Physician



Medical education working and supports continued investment

- >152 dinner events conducted with >2,017 attendees
- 25,220 viewers of Medscape
 CME program (as of June 15th)
- Presence at 7 national medical congresses since launch





Pathways to mobilizing Cologuard® adoption Influencing Activating Securing People Physicians Coverage exact sciences

Activating people using multi-channel approach





Activating people using multi-channel approach




Patient oriented physician discussion guide downloads driving orders



- >27,000 discussion guide downloads
- ~700 discussion guide downloads per week




Pilot of regional marketing campaigns
















Expanded marketing in these regions driving increased orders






Pathways to mobilizing Cologuard® adoption Influencing Activating Securing People Physicians Coverage exact sciences

Securing reimbursement through two steps Commitment by payer to cover 1. Coverage Cologuard® at undefined rate In-network rate that absolves 2. Contracting patient from payment



Current landscape for insured patients 50+ years of age















Growth strategy to expand coverage and contracting

- Active conversations with 200 key payers
- Building internal resources dedicated to securing coverage
- Average commercial contracted rate above Medicare rate (\$493)

Compelling payer value proposition

Quality of Care	NEJM publication – 92% sensitive, Medicare NCD
Member Satisfaction	Easy, non-invasive test and compliance program
Cost Savings	Alternative to costly colonoscopy



Guidelines promote use and expand coverage



Included ACS guidelines every 3 years



 Draft guidance expected Q3 2015; final rating expected in 2016



Ordering behavior expected to change with USPSTF "A" or "B" rating



Quality Measures

Credit for screening with Cologuard®

- Supports physicians ordering behavior
- HEDIS: National Committee on Quality Assurance (NCQA)
- STARS: Medicare Advantage (CMS)

Commercial Coverage

Insurance payment for Cologuard®

 Under Affordable Care Act, commercial payers must cover Cologuard[®]



Cologuard®: A value proposition driving compliance

- Regulatory approval
- Validated clinical utility
- Broad existing coverage
- Recommended in guidelines
- Cost savings


73%

Cologuard® compliance rate

The illustration is launch to date as of June 19th




Adding new people to America's screening population





Source: Exact Sciences Laboratories LLC data (unpublished), n = 2,997







Pathways to mobilizing Cologuard® adoption Securing Influencing Activating Physicians People Coverage exact sciences